Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
Bodd MH, Locke SC, Wolf SP, Antonia S, Crawford J, Hartman J, Herring KW, Ready NE, Stinchcombe TE, Troy JD, Williams C, Clarke JM, LeBlanc TW. Bodd MH, et al. Among authors: stinchcombe te. Lung Cancer. 2023 Jan;175:17-26. doi: 10.1016/j.lungcan.2022.11.010. Epub 2022 Nov 21. Lung Cancer. 2023. PMID: 36442383
Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105.
Salama JK, Stinchcombe TE, Gu L, Wang X, Morano K, Bogart JA, Crawford JC, Socinski MA, Blackstock AW, Vokes EE; Cancer and Leukemia Group B. Salama JK, et al. Among authors: stinchcombe te. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e269-74. doi: 10.1016/j.ijrobp.2011.01.056. Epub 2011 Apr 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 21477940 Free PMC article. Clinical Trial.
A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy.
Weiss JM, Villaruz LC, Socinski MA, Ivanova A, Grilley-Olson J, Dhruva N, Stinchcombe TE. Weiss JM, et al. Among authors: stinchcombe te. Lung Cancer. 2014 Nov;86(2):288-90. doi: 10.1016/j.lungcan.2014.08.011. Epub 2014 Aug 26. Lung Cancer. 2014. PMID: 25201721 Free PMC article. Clinical Trial.
Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma.
Zhao N, Wilkerson MD, Shah U, Yin X, Wang A, Hayward MC, Roberts P, Lee CB, Parsons AM, Thorne LB, Haithcock BE, Grilley-Olson JE, Stinchcombe TE, Funkhouser WK, Wong KK, Sharpless NE, Hayes DN. Zhao N, et al. Among authors: stinchcombe te. Lung Cancer. 2014 Nov;86(2):255-61. doi: 10.1016/j.lungcan.2014.08.013. Epub 2014 Aug 30. Lung Cancer. 2014. PMID: 25224251 Free PMC article.
MEK inhibition in non-small cell lung cancer.
Stinchcombe TE, Johnson GL. Stinchcombe TE, et al. Lung Cancer. 2014 Nov;86(2):121-5. doi: 10.1016/j.lungcan.2014.09.005. Epub 2014 Sep 16. Lung Cancer. 2014. PMID: 25257766 Free PMC article. Review.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, Levy BP, Nair SG, Zalcman G, Wolf J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. Rizvi NA, et al. Among authors: stinchcombe te. Lancet Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9. Epub 2015 Feb 20. Lancet Oncol. 2015. PMID: 25704439 Free PMC article. Clinical Trial.
185 results